Drugs / HPV nonavalent vaccine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | Japan (PMDA) | シルガード®9 | anal cancer and precancerous lesions, genital warts in males | 2024-11-15 | “「シルガード®9」について、以下に関する製造販売承認事項一部変更承認申請を行いましたのでお知らせいたします。” msd.co.jp ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07156084 | Sep 2025 → Feb 2026 overdue | — | Canadian Immunization Research Network | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-15 | MSD R&D (China) Co., Ltd. | Regulatory ９価HPVワクチン「シルガード®９水性懸濁筋注シリンジ」男性への接種対象拡大と肛門がんの予防の適応追加について承認を申請 msd.co.jp ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-15 | MSD R&D (China) Co., Ltd. | ９価HPVワクチン「シルガード®９水性懸濁筋注シリンジ」男性への接種対象拡大と肛門がんの予防の適応追加について承認を申請 msd.co.jp ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV nonavalent vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07156084 ↗ |
| Known as | Gardasil-9 | “HPV nonavalent vaccine (Gardasil-9)” NCT07156084 ↗ |
| Modality | Vaccine | “nonavalent (9vHPV) vaccine” NCT07156084 ↗ |